Genedrive collects £0.76m R&D tax credit
5th Jun 2026 12:12
(Sharecast News) - Genedrive said on Friday that it had received a research and development tax credit refund of about £0.76m from HMRC.
Read moreSussex NHS trust moves to routine use of Genedrive test
5th May 2026 12:10
(Sharecast News) - Genedrive said on Tuesday that the University Hospitals Sussex NHS Foundation Trust had moved its MT-RNR1 test into routine clinical service for use in neonatal intensive care units.
Read moreGenedrive reports doubling of full-year revenue
5th Dec 2025 08:55
(Sharecast News) - Genedrive reported a doubling of revenue and other income to £1m for the year ended 30 June on Friday, from £0.5m a year earlier, as the point-of-care pharmacogenetic testing company shifted from a pre-commercial to a commercial focus.
Read moreGenedrive signals potential £1m loan from shareholder David Nugent
31st Oct 2025 10:14
(Sharecast News) - AIM-listed Genedrive said on Friday that shareholder David Nugent had shown "willingness" to make a cash injection into the point-of-care pharmacogenetic testing company.
Read moreGenedrive's Saudi Arabian distribution partner inks MoU with Ministry of Health
28th Oct 2025 08:26
(Sharecast News) - Pharmacogenetic testing business Genedrive said on Tuesday that its exclusive distribution partner in the Kingdom of Saudi Arabia, iDeal iDea for Medical Equipment Technology, has signed a memorandum of understanding with the Saudi Arabian Ministry of Health.
Read moreGenedrive flags doubling of full-year income
11th Aug 2025 15:50
(Sharecast News) - Genedrive said in an update on Monday that its full-year income for the 12 months ended June doubled to around £1m, from £0.5m a year earlier, driven by stronger second-half sales.
Read moreGenedrive secures CE certification for CYP2C19 ID Kit
30th May 2025 11:44
(Sharecast News) - Genedrive announced on Friday that it has secured CE certification for its CYP2C19 ID Kit under the European In Vitro Diagnostic Regulation (IVDR), allowing the pharmacogenetic test to be marketed and used across the EU and in certain non-European countries that recognise CE-IVD marking.
Read moreGenedrive upbeat on publication of clinical performance data
27th Dec 2024 12:27
(Sharecast News) - Point-of-care pharmacogenetic testing specialist Genedrive announced on Friday that clinical performance data for its Genedrive CYP2C19-ID Kit had been published in the Journal of Molecular Biology.
Read moreGenedrive full-year revenue rises
29th Nov 2024 13:43
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive reported a significant increase in revenue in its full-year results on Friday.
Read moreDirector dealings: Genedrive chairman snaps up shares
15th Aug 2024 15:15
(Sharecast News) - Genedrive revealed on Thursday that chairman Ian Gilham had acquired 1.0m shares in the AIM-listed pharmacogenetic testing company.
Read moreGenedrive makes first commercial sales of CYP2C19-ID testing kit
12th Aug 2024 09:01
(Sharecast News) - Pharmacogenetic testing firm Genedrive said on Monday that it has made the first UK commercial sales of its CYP2C19-ID testing kit.
Read moreGenedrive test ordered by five Manchester area hospitals
24th May 2024 12:24
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced on Friday that it has received initial orders for its Genedrive MT-RNR1 products from five additional UK hospitals in the Greater Manchester area.
Read moreGenedrive shares jump on NICE test recommendation
3rd Apr 2024 13:54
(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.
Read moreGenedrive receives R&D tax credit, plans fundraise
15th Mar 2024 14:27
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.
Read moreGenedrive set to apply for NICE EVA funding
19th Feb 2024 10:56
(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).
Read more